Research programme: purinergic P2 receptor antagonists - Merck

Drug Profile

Research programme: purinergic P2 receptor antagonists - Merck

Alternative Names: AF-220; AF-221; AF-742; RO-4

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Merck & Co; Roche
  • Class Diaminopyrimidines; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Pain
  • Preclinical Overactive bladder

Most Recent Events

  • 11 Sep 2013 Phase-0 development is ongoing in USA
  • 26 Aug 2010 Preclinical trials in Overactive bladder in Canada (PO)
  • 26 Aug 2010 Pharmacodynamics data from a preclinical trial in overactive bladder presented at the 40th International Continence Society and the 35th International UroGynecological Association (Joint Meeting) (ICS/IUGA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top